Mid-range probing - Towards range-guided particle therapy

Research output: Contribution to journalArticle

Abstract

Particle therapy can achieve excellent dose localization but is sensitive to range uncertainty. Therefore, online in vivo range verification before treatment is critical for treatment safety and quality assurance. We introduce a novel range-probing technique that uses mid-range treatment spots selected from the treatment plan as probing beams to be delivered before other treatment spots in pencil beam scanning. The probing spot signal can be acquired by an in-beam positron emission tomography (PET) scanner, and the reconstructed spot positions are compared with pre-calculated positions to measure the range shift. Mid-range probing ensures that the Bragg peaks stay inside the tumor even with significant range variation from the plan. Single-layered spots enable easier spot detection than multi-layered spots without cross-layered spot smearing. With therapeutic dose, the probing beam offers higher positron activities and range detectability than the low-dose imaging beam by up to two orders of magnitude, without exposing patients to extra radiation. Higher positron activities allow sufficient signal statistics in shorter acquisition time, therefore reducing metabolic washout of positron emitters. Thus, range shifts from the plan can be measured easily. We also describe two online range-compensated plan modification methods. We apply correction, if the range shift is above a certain tolerance. We studied feasibility using simulated particle treatment plans with online anatomical changes. For illustration, we demonstrate range shift measurement using simulated probing dose. The proposed range probing and correction effectively handled range shifts in the simulated cases. Both range-compensated adaptation and optimization accounted for online changes so that the delivered dose matched the planned dose. With a dedicated online in-beam PET scanner and phantom and clinical studies, which are currently being developed, this novel strategy may open up a range-guided particle therapy1 paradigm.

Original languageEnglish (US)
Article number13NT01
JournalPhysics in Medicine and Biology
Volume63
Issue number13
DOIs
StatePublished - Jun 27 2018

Fingerprint

Electrons
Therapeutics
Positron-Emission Tomography
Uncertainty
Radiation
Safety
Neoplasms
Clinical Studies

Keywords

  • intra-treatment adaptation
  • mid-range probing
  • online range verification
  • range-guided particle therapy

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this

Mid-range probing - Towards range-guided particle therapy. / Chen, Mingli; Zhong, Yuncheng; Shao, Yiping; Jiang, Steve; Lu, Weiguo.

In: Physics in Medicine and Biology, Vol. 63, No. 13, 13NT01, 27.06.2018.

Research output: Contribution to journalArticle

@article{bccf715e15d6480e9f07514583526b21,
title = "Mid-range probing - Towards range-guided particle therapy",
abstract = "Particle therapy can achieve excellent dose localization but is sensitive to range uncertainty. Therefore, online in vivo range verification before treatment is critical for treatment safety and quality assurance. We introduce a novel range-probing technique that uses mid-range treatment spots selected from the treatment plan as probing beams to be delivered before other treatment spots in pencil beam scanning. The probing spot signal can be acquired by an in-beam positron emission tomography (PET) scanner, and the reconstructed spot positions are compared with pre-calculated positions to measure the range shift. Mid-range probing ensures that the Bragg peaks stay inside the tumor even with significant range variation from the plan. Single-layered spots enable easier spot detection than multi-layered spots without cross-layered spot smearing. With therapeutic dose, the probing beam offers higher positron activities and range detectability than the low-dose imaging beam by up to two orders of magnitude, without exposing patients to extra radiation. Higher positron activities allow sufficient signal statistics in shorter acquisition time, therefore reducing metabolic washout of positron emitters. Thus, range shifts from the plan can be measured easily. We also describe two online range-compensated plan modification methods. We apply correction, if the range shift is above a certain tolerance. We studied feasibility using simulated particle treatment plans with online anatomical changes. For illustration, we demonstrate range shift measurement using simulated probing dose. The proposed range probing and correction effectively handled range shifts in the simulated cases. Both range-compensated adaptation and optimization accounted for online changes so that the delivered dose matched the planned dose. With a dedicated online in-beam PET scanner and phantom and clinical studies, which are currently being developed, this novel strategy may open up a range-guided particle therapy1 paradigm.",
keywords = "intra-treatment adaptation, mid-range probing, online range verification, range-guided particle therapy",
author = "Mingli Chen and Yuncheng Zhong and Yiping Shao and Steve Jiang and Weiguo Lu",
year = "2018",
month = "6",
day = "27",
doi = "10.1088/1361-6560/aaca1b",
language = "English (US)",
volume = "63",
journal = "Physics in Medicine and Biology",
issn = "0031-9155",
publisher = "IOP Publishing Ltd.",
number = "13",

}

TY - JOUR

T1 - Mid-range probing - Towards range-guided particle therapy

AU - Chen, Mingli

AU - Zhong, Yuncheng

AU - Shao, Yiping

AU - Jiang, Steve

AU - Lu, Weiguo

PY - 2018/6/27

Y1 - 2018/6/27

N2 - Particle therapy can achieve excellent dose localization but is sensitive to range uncertainty. Therefore, online in vivo range verification before treatment is critical for treatment safety and quality assurance. We introduce a novel range-probing technique that uses mid-range treatment spots selected from the treatment plan as probing beams to be delivered before other treatment spots in pencil beam scanning. The probing spot signal can be acquired by an in-beam positron emission tomography (PET) scanner, and the reconstructed spot positions are compared with pre-calculated positions to measure the range shift. Mid-range probing ensures that the Bragg peaks stay inside the tumor even with significant range variation from the plan. Single-layered spots enable easier spot detection than multi-layered spots without cross-layered spot smearing. With therapeutic dose, the probing beam offers higher positron activities and range detectability than the low-dose imaging beam by up to two orders of magnitude, without exposing patients to extra radiation. Higher positron activities allow sufficient signal statistics in shorter acquisition time, therefore reducing metabolic washout of positron emitters. Thus, range shifts from the plan can be measured easily. We also describe two online range-compensated plan modification methods. We apply correction, if the range shift is above a certain tolerance. We studied feasibility using simulated particle treatment plans with online anatomical changes. For illustration, we demonstrate range shift measurement using simulated probing dose. The proposed range probing and correction effectively handled range shifts in the simulated cases. Both range-compensated adaptation and optimization accounted for online changes so that the delivered dose matched the planned dose. With a dedicated online in-beam PET scanner and phantom and clinical studies, which are currently being developed, this novel strategy may open up a range-guided particle therapy1 paradigm.

AB - Particle therapy can achieve excellent dose localization but is sensitive to range uncertainty. Therefore, online in vivo range verification before treatment is critical for treatment safety and quality assurance. We introduce a novel range-probing technique that uses mid-range treatment spots selected from the treatment plan as probing beams to be delivered before other treatment spots in pencil beam scanning. The probing spot signal can be acquired by an in-beam positron emission tomography (PET) scanner, and the reconstructed spot positions are compared with pre-calculated positions to measure the range shift. Mid-range probing ensures that the Bragg peaks stay inside the tumor even with significant range variation from the plan. Single-layered spots enable easier spot detection than multi-layered spots without cross-layered spot smearing. With therapeutic dose, the probing beam offers higher positron activities and range detectability than the low-dose imaging beam by up to two orders of magnitude, without exposing patients to extra radiation. Higher positron activities allow sufficient signal statistics in shorter acquisition time, therefore reducing metabolic washout of positron emitters. Thus, range shifts from the plan can be measured easily. We also describe two online range-compensated plan modification methods. We apply correction, if the range shift is above a certain tolerance. We studied feasibility using simulated particle treatment plans with online anatomical changes. For illustration, we demonstrate range shift measurement using simulated probing dose. The proposed range probing and correction effectively handled range shifts in the simulated cases. Both range-compensated adaptation and optimization accounted for online changes so that the delivered dose matched the planned dose. With a dedicated online in-beam PET scanner and phantom and clinical studies, which are currently being developed, this novel strategy may open up a range-guided particle therapy1 paradigm.

KW - intra-treatment adaptation

KW - mid-range probing

KW - online range verification

KW - range-guided particle therapy

UR - http://www.scopus.com/inward/record.url?scp=85049926700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049926700&partnerID=8YFLogxK

U2 - 10.1088/1361-6560/aaca1b

DO - 10.1088/1361-6560/aaca1b

M3 - Article

VL - 63

JO - Physics in Medicine and Biology

JF - Physics in Medicine and Biology

SN - 0031-9155

IS - 13

M1 - 13NT01

ER -